Continuing the fight against advanced colorectal cancer: New and future treatment options

Anti-Cancer Drugs

Volumn 9, Issue 1, 1998, Pages 18-28

  Bleiberg, Harry ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Colorectal cancer; Fluorouracil; Irinotecan; Oxaliplatin; Treatment outcome; ZD1694

Indexed keywords

2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; 5 ETHYNYLURACIL; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BATIMASTAT; BISNAFIDE MESYLATE; CARCINOEMBRYONIC ANTIBODY; DNA TOPOISOMERASE INHIBITOR; DROLOXIFENE; EDRECOLOMAB; FLUOROURACIL; GASTRIN 17; IMMUNOMODULATING AGENT; IMMUNOSTIMULATING AGENT; IRINOTECAN; METESIND GLUCURONATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MN 14; NOLATREXED; OXALIPLATIN; PEMETREXED; PLATINUM DERIVATIVE; RA 700; RALTITREXED; ROQUINIMEX; THROMBOCYTE FACTOR 4; THYMIDYLATE SYNTHASE INHIBITOR; TOPOTECAN; UNCLASSIFIED DRUG; XOMAZYME;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG MECHANISM; DYSESTHESIA; GENE THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSORY NEUROPATHY; TREATMENT OUTCOME; VOMITING;

EID: 0031912341     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199801000-00002     Document Type: Review

References (83)

1. Estève J, Kricker A, Ferlay J, Parkin DM. Facts and figures of cancer in the European community. Lyons: International Agency for Research on Cancer 1993.
2. Gordon NLM, Dawson AA, Bennett B, Innes G, Eremin O, Jones PF. Outcome in colorectal adenocarcinoma: two seven-year studies of a population. Br Med J 1993; 307: 707-10.
3. Cohen AM, Minsky BD, Schilsky RL. Colon cancer. In: De Vita Jr VT, Hellmann S, Rosenberg SA, eds. Cancer: principles & practice of oncology. Philadelphia, PA: Lippincott 1993: 929-77.
4. Francini G, Petrioli R, Lorenzini L, et al. Folinic acid 5-fluorouracil as adjuvant therapy in colon cancer. Gastroenterology 1994; 106: 899-906.
5. Moertel CG, Fleming TR, MacDonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122: 321-6.
6. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-44.
7. Abulafi AM, Williams NS. Local recurrence of colorectal cancer: the problem, the mechanisms, management and adjuvant therapy. Br J Surg 1994; 81: 7-19.
8. Schiessel R, Wunderlich M, Herbst F. Local recurrence of colorectal cancer effect of early detection and aggressive surgery. Br J Surg 1986; 73: 342-4.
9. Pollard SG, Macfarlane R, Everett WG. Surgery for recurrent colorectal carcinoma - is it worthwhile? Ann R Coll Surg Engl 1989; 71: 2938.
10. Lehnert T, Otto G, Herfarth C. Therapeutic modalities and prognostic factors for primary and secondary liver tumours. World J Surg 1995; 19: 252-63.
11. Scheele J, Stang R, Altendorf-Hoffman A, Paul MD. Resection of colorectal liver metastases. World J Surg 1995; 19: 57-71.
12. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10: 904-11.
13. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 752-5.
14. Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6: 267-74.
15. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
16. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994; 330: 1136-42.
17. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-17.
18. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: 960-9.
19. Seifert P, Baker LH, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123-8.
20. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425-32.
21. Labianca R, Pancera G, Cesana B, Clerici M, Montinari F, Luporini G. Cisplatin and 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study. Eur J Clin Oncol 1988; 24: 1579-81.
22. Bleiberg H, Vanderlinden B, Buyse M, et al. Randomized phase II study of a combination of cisplatin (DDP), 5-fluorouracil (5-FU) and allopurinol (HHP) versus 5-fluorouracil in colorectal cancer. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. Cancer Invest 1990; 8: 471-5.
23. Moertel CG, Schutt AJ, Hahn RG, Reitemeier RJ. Brief communication. Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-1,3-cis(2-chloroethyl)-1-nitrosourea and vincristine. J Natl Cancer Inst 1975; 54: 69-71.
24. Engstrom P, MacIntyre J, Douglass H, et al. Combination chemotherapy of advanced bowel cancer. Proc Am Ass Cancer Res 1978; 19: 384 (abstr).
25. Kemeny N, Yagoda A, Braun D Jr, Golbey R. A randomized study of two different schedules of methyl CCNU, 5-FU and vincristine for metastatic colorectal carcinoma. Cancer 1979; 43: 78-82.
26. Hohn DC, Stagg RJ, Freidman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group trial. J Clin Oncol 1989; 7: 1646-54.
27. Martin JK, O'Connell MJ, Wienand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 1990; 125: 1022-7.
28. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992; 10: 1112-8.
29. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepaticartery floxuridine infusion for colorectal liver metastases. Lancet 1994; 344: 1255-60.
30. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994; 20: 73-96.
31. Hsiang YH, Lihou MG, Liu LF. Arrest of replication forks by drug-stabilised topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989; 49: 5077-82.
32. Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046-8.
33. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 1970; 54: 461-70.
34. Gallo RC, Whang-Peng J, Adamson RH. Studies on the antitumour activity, mechanism of action and cell cycle effects of camptothecin. J Natl Cancer Inst 1971; 46: 789-95.
35. Shimada Y, Yashino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909-13.
36. Conti JA, Kemeny N, Saltz L, Tong W, Chou TC, Pulliam M. Irinotecan (CPT-11) is an active agent in untreated patients with metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 1994; 13: 195 (abstr 565).
37. Pitot HC, Wender D, O'Connell MJ, Wieand HS, Mailliard JA. A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group (NCCTG) study. Proc Am Soc Clin Oncol 1994; 13: 197 (abstr 573).
38. Rothenberg ML, Eckardt JR, Burris III HA, et al. Irinotecan (CPT-11) as second line therapy for PTS with 5-FU-refractory colorectal cancer. Proc Am Soc Clin Oncol 1994; 13: 198 (abstr 578).
39. Rougier P, Bugat R, Brunet P, et al. Clinical efficacy of CPT-11 in patients with inoperable advanced colorectal cancer (CRC): results of a multicentric open phase II study. In: 5th Int Congr of Anti-Cancer Chemotherapy, Paris, France, 1995: S775 (abstr).
40. Bugat R. CPT-11 in the treatment of colorectal cancer (CRC): safety profile. In: 5th Int Congr of Anti-Cancer Chemotherapy, Paris, France 995: S778 (abstr).
41. Abigerges D, Armand JP, Chabot G, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86: 446-9.
42. Goncalves E, de-Costa L, Abigerges D, Armand JP. A new enkephalinase inhibitor as an alternative to loperamide in the prevention of diarrhea induced by CPT-11. J Clin Oncol 1995; 13: 2144-6.
43. Hagipantelli R, Saliba F, Misset JL, et al. Pathophysiology and therapy of irinotecan (CPT-11) induced delayed diarrhea (DD). A prospective assessment. Proc Am Soc Clin Oncol 1995; 14: 464 (abstr 1499).
44. Sugarman SM, Ajani JA, Daugherty K, et al. A phase II trial of topotecan (TPT) for the treatment of advanced measureable colorectal cancer. Proc Am Soc Clin Oncol 1994; 13: 224 (abstr 684).
45. Emerson DL, Vuong DL, McIntyre MS, et al. In vivo efficacy of two new water-soluble camptothecin analogs in the human cancer xenograft model. Proc Am Ass Cancer Res 1993; 34: 419 (abstr).
46. O'Dwyer P, Cassidy J, Kunka R, et al. Phase I trial of GG211, a new topoisomerase inhibitor, using a 72 hour continuous infusion (CI). Proc Am Soc Clin Oncol 1995; 14: 471 (abstr 1525).
47. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215-37.
48. Jackman AL, Gibson W, Brown M, Kimbell R, Boyle FT. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Adv Exp Med Biol 1993; 339: 265-76.
49. Zalcberg JR, Cunningham D, Van Cutsem E, et al. Tomudex® (ZD1694), a novel thymidylate synthase inhibitor has substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J Clin Oncol 1996; 14: 716-21.
50. Cunningham D, Zalberg JR, Rath U, et al. Tomudex (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995; 31A: 1945-54.
51. Aaronsen NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
52. Shih C, Grindley GB, Engelhardt JA, et al. N-[4-[2-(2-amino-4(3H)-oxo-7H-pyrrolo [2,3-d] pyrimidin-5-yl) ethyl] benzoyl]-L-glutamatic acid: a new and potent inhibitor of thymidylate synthase. In: 7th NCI-EORTC Symp on New Drugs Cancer Therapy, Amsterdam 1992: 134 (abstr).
53. Vasey PA, Calvert AH, Kaye SB, Cassidy J. Clinical phase I study of LY231514 (an inhibitor of thymidylate synthase) using a daily × 5 q 21 schedule. Ann Oncol 1994; 5 (suppl 5): 131 (abstr 237).
54. Johnston AL, Shetty BV, Webber S, et al. Experimental antitumor activity of AG-331, a novel lipophilic thymidylate synthase inhibitor. In: 7th NCI-EORTC Symp on New Drugs Cancer Therapy, Amsterdam 1992: 131 (abstr).
55. Stephens TC, Smith MN, McCloskey ML, et al. ZD9331, a novel non-polyglutamated thymidylate synthase (TS) inhibitor: in vivo antitumour efficacy and toxicity to normal murine tissues. Proc Am Ass Cancer Res 1994; 35: 305 (abstr 1816).
56. Banks SD, Waters KA, Barrett LL, et al. Destruction of WiDr multicellular tumor spheroids with the novel thymidylate synthase inhibitor 1843U89 at physiological thymidine concentrations. Cancer Chemother 1994; 33: 455-9.
57. Brienza S, Fandi A, Hugret F, et al. Neurotoxicity of long run oxaliplatin (L-OHP®) therapy. Proc Am Ass Cancer Res 1993; 34: 406 (abstr 2421).
58. Levi F, Perpoint B, Garufi C, et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 29A: 1280-4.
59. Brienza S, Levi F, Valori VM, et al. Intensified (every 2 weeks) chronotherapy with 5-fluorouracil (5-FU), folinic acid (FA) and oxaliplatin (L-OHP) in previously treated patients (pts) with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1993; 12: 197 (abstr 577).
60. Lévi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 1992; 69: 893-900.
61. Lévi F, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608-17.
62. de Gramont A, Tournigand C, Louvet C, et al. High-dose folinic acid, 5-fluorouracil 48H-infusion and oxaliplatin in metastatic colorectal cancer. In: 5th Int Congr of Anti-Cancer Chemotherapy, Paris, France 1995: 0269 (abstr).
63. Garufi C, Brienza S, Bensmaine MA, et al. Addition of oxaliplatin (L-OHP®) to chronomodulated (CM) 5-fluorouracil and folinic acid (FA) for reversal of acquired chemoresistance in patients with advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 1995; 14: 192 (abstr 446).
64. Diaz-Rubio E, Marty M, Extra JM, et al. Multicentric phase II study with oxaliplatin (L-OHP®) in 5-Fu refractory patients with advanced colorectal cancer (ACC). In: 5th Int Congr of Anti-Cancer Chemotherapy, Paris, France 1995: 0721 (abstr).
65. Mellstedt H, Frödin J-E, Masucci G, et al. The therapeutic use of monoclonal antibodies in colorectal carcinoma. Semin Oncol 1991; 18: 462-77.
66. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal cancer. Lancet 1994; 343: 1177-83.
67. Takahashi T, Yamaguchi T, Kitamura K, Noguchi A, Honda M, Otsuji E. Follow-up study of patients treated with monoclonal antibody-drug conjugate: report of 77 cases with colorectal cancer. Jpn J Cancer Res 1993; 84: 976-81.
68. Sharkey RM, Goldenberg DM, Murthy S, et al. Clinical evaluation of tumor targeting with a high-affinity anti-carcinoembryonic-antigen-specific murine monoclonal antibody, MN-14. Cancer 1993; 71: 208296.
69. Denton GW, Durrant LG, Hardcastle JD, Austin EB, Sewell HF, Robins RA. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int J Cancer 1994; 57: 10-4.
70. King DJ, Antonin P, Turner A, et al. Development of an effective anti-tumour agent from the monoclonal antibody A33. J Immunother 1994; 16: 156 (abstr 32).
71. Byers VS, Rodvien R, Grant K, et al. Phase I study of monoclonal antibody-ricin A chain immunotoxin Xoma Zyme-791 in patients with metastatic colorectal cancer. Cancer Res 1989; 49: 6153-60.
72. Chart RVJ, Martell BA, Gross JL, et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992; 52: 127-31.
73. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthoptic model in nude mice. Cancer Res 1994; 54: 4726-8.
74. Houghton PJ, Cheshire PJ, Hallman JC, et al. Evaluation of a novel bis-naphthalimide anticancer agent, DMP840, against human xenografts derived from adult, juvenile and pediatric cancers. Cancer Chemother Pharmacol 1994; 33: 265-72.
75. Nienhaus P Queißer W, Heim ME, Pechan R. Phase II study of droloxifene for treatment of metastatic colorectal carcinoma. Onkologie 1991; 14: 401-5.
76. Dornschneider G, Limmer J, Schmil C, Krams M, Izbicki JR. Anti-estroglancenic therapy in metastatic colorectal cancer. Tumor Diagn Ther 1994; 15: 247-9.
77. Mikulski SM, Grossman AM, Carter PW. Phase I human clinical trial of ONCONASE (Rm) (P-30 protein) administered intravenously on a weekly schedule in cancer patients with solid tumours. Int J Oncol 1993; 3: 57-64.
78. Baccanari DP, Davis ST, Knick VC, Spector T. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumour efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 1993; 90: 11064-8.
79. Sharpe RJ, Byers HR, Scott CF, Bauer EI, Maione TE. Growth inhibition of marine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 1990; 82: 848-53.
80. Onier N, Lejeune P, Martin M, et al. Involvement of T lymphocytes in curative effect of a new immunomodulator OM163 on rat colon cancer metastases. Eur J Cancer 1993; 29A: 2003-9.
81. Foon KA, Chakraborty M, John WJ, Sherratt A, Kohler-H, Bhattacharya-Chatterjee M. Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype vaccine. J Clin Invest 1995; 96: 334-42.
82. Blakey DC, Davies DH, Dowell RI, et al. ZD2767: a potent and selective system for antibody-directed enzyme prodrug therapy (ADEPT). In: Proc Tufton Charitable Trust Conf: New Antibody Technology and the Emergence of Useful Cancer Therapy 1994; 83 (poster abstr).
83. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA. In vivo antitumour activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993; 53: 4619-26.